Breaking News Instant updates and real-time market news.

CHRS

Coherus Biosciences

09:19
06/12/17
06/12
09:19
06/12/17
09:19

Coherus Biosciences selloff an overreaction, says Standpoint Research

Standpoint Research analyst Ronnie Moas views this morning's selloff in shares of Coherus Biosciences as an overreaction. The analyst maintains a Buy rating on the name but pushed out his $40 price target to 2019 from 2018 following the company's complete response letter from the FDA. The FDA has "merely requested" additional information, which Coherus can provide, Moas tells investors in an email after listening to the company's conference call. The stock in premarket trading is down 30%, or $6.26, to $14.39.

  • 12

    Jun

CHRS Coherus Biosciences

05/15/17
MAXM
05/15/17
NO CHANGE
Target $43
MAXM
Buy
Maxim sees probability of Humira patent ruling favoring Coherus
Maxim analyst Jason McCarthy said if Amgen's (AMGN) '135 patent for Humira is invalidated on May 17, Coherus Biosciences (CHRS) could potentially launch CHS-1420, its proposed biosimilar of adalimumab, in 2018, four years before others competing to launch a Humira biosimilar. He believes the probability favors Coherus, citing the fact that the company's focus on developing biosimilars is based on IP first. Coherus will need to raise capital again, but the outcome of the Humira patent decision and the upcoming approval decision for Neulasta on June 9 will determine at what valuation, said McCarthy, who has a Buy rating and $43 price target on Coherus shares.
05/17/17
SBSH
05/17/17
NO CHANGE
Target $38
SBSH
Buy
Citi sees up to $8/share upside for Coherus on patent win
Citi analyst Mohit Bansal sees $4 to $8 per share upside for Coherus Biosciences (CHRS) after the Patent Trial and Appeal Board ruled in favor of the company's petitions for Inter Partes Review of AbbVie's (ABBV) '135 Patent. The stock in premarket trading is up 9%, or $1.95, to $24.00. The win makes a Humira biosimilar launch from Coherus more realistic, Bansal tells investors in a research note. Further, he believes the news makes an anti-TNF franchise partnership for Coherus with big bio-pharma more likely. He thinks a deal could be announced in the second half of 2017. Bansal keeps a Buy rating on Coherus with a $38 price target.
05/17/17
MAXM
05/17/17
NO CHANGE
Target $44
MAXM
Buy
Coherus could beat Humira competitors to market by 4 years, says Maxim
Maxim analyst Jason McCarthy said the invalidation of AbbVie's (ABBV) dosing patent for Humira is a "major victory" for Coherus Biosciences (CHRS) that has reduced its risk profile. The last IP hurdle to launching a Humira biosimilar is formulation, where Coherus has the advantage, said McCarthy, who believes the company could be first to market with a biosimilar by late 2018, which would be four years or more ahead of its competition. He raised his price target on Coherus shares to $44 from $43 and keeps a Buy rating on the stock, which is up $1.95, or 8.8%, to $24 in pre-market trading.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.

TODAY'S FREE FLY STORIES

PANW

Palo Alto Networks

$142.61

-0.115 (-0.08%)

16:12
11/20/17
11/20
16:12
11/20/17
16:12
Earnings
Palo Alto Networks sees Q2 adjusted EPS 78c-80c, consensus 77c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

RVNC

Revance

$24.60

-1.35 (-5.20%)

16:11
11/20/17
11/20
16:11
11/20/17
16:11
Hot Stocks
Revance: FDA grants orphan drug designation for RT002 »

Revance Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PANW

Palo Alto Networks

$142.24

-0.48 (-0.34%)

16:10
11/20/17
11/20
16:10
11/20/17
16:10
Earnings
Palo Alto Networks reports Q1 adjusted EPS 74c, consensus 69c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

INTU

Intuit

$157.78

1.23 (0.79%)

16:09
11/20/17
11/20
16:09
11/20/17
16:09
Earnings
Intuit reports Q1 adjusted EPS 11c, consensus 5c »

Reports Q1 revenue $886M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

A

Agilent

$70.00

1.205 (1.75%)

16:08
11/20/17
11/20
16:08
11/20/17
16:08
Earnings
Agilent sees FY18 adjusted EPS $2.50-$2.56, consensus $2.59 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 30

    Nov

MHK

Mohawk

$276.40

4.2 (1.54%)

16:08
11/20/17
11/20
16:08
11/20/17
16:08
Hot Stocks
Mohawk to acquire Godfrey Hirst Group, terms not disclosed »

Mohawk Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

A

Agilent

$69.96

1.17 (1.70%)

16:07
11/20/17
11/20
16:07
11/20/17
16:07
Earnings
Agilent sees Q1 adjusted EPS 55c-57c, consensus 60c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 30

    Nov

CLSN

Celsion

$2.14

0.14 (7.00%)

16:07
11/20/17
11/20
16:07
11/20/17
16:07
Initiation
Celsion initiated  »

Celsion initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$28.27

0.37 (1.33%)

16:07
11/20/17
11/20
16:07
11/20/17
16:07
Earnings
Urban Outfitters reports Q3 EPS 41c, consensus 33c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

VIPS

Vipshop

$9.25

-0.53 (-5.42%)

16:07
11/20/17
11/20
16:07
11/20/17
16:07
Earnings
Breaking Earnings news story on Vipshop »

Vipshop sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.92

1.125 (1.64%)

16:06
11/20/17
11/20
16:06
11/20/17
16:06
Earnings
Agilent reports Q4 adjusted EPS 67c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 30

    Nov

VIPS

Vipshop

$9.27

-0.51 (-5.21%)

16:06
11/20/17
11/20
16:06
11/20/17
16:06
Earnings
Vipshop reports Q3 adjusted EPS 14c, consensus 14c »

Reports Q3 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ARNC

Arconic

$23.87

0.02 (0.08%)

16:05
11/20/17
11/20
16:05
11/20/17
16:05
Hot Stocks
Arconic to install new horizontal heat treat furnace at Davenport Works facility »

Arconic announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIFI

SI Financial

$14.95

0.35 (2.40%)

16:04
11/20/17
11/20
16:04
11/20/17
16:04
Hot Stocks
SI Financial Chief Credit Officer Gerald Coia to retire »

SI Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTA

Enanta

16:03
11/20/17
11/20
16:03
11/20/17
16:03
Earnings
Enanta Pharmaceuticals reports Q4 EPS $1.86, consensus $2.13 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NBIX

Neurocrine

, ZBH

Zimmer Biomet

$112.03

0.42 (0.38%)

16:02
11/20/17
11/20
16:02
11/20/17
16:02
Hot Stocks
Neurocrine names Matt Abernethy as CFO »

Neurocrine Biosciences…

NBIX

Neurocrine

ZBH

Zimmer Biomet

$112.03

0.42 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

  • 14

    Dec

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

, PEGI

Pattern Energy

$22.13

0.14 (0.64%)

15:46
11/20/17
11/20
15:46
11/20/17
15:46
Periodicals
8point3 draws interest from Capital Dynamics, Pattern Energy, Bloomberg says »

Capital Dynamics and…

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

PEGI

Pattern Energy

$22.13

0.14 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

VRX

Valeant

$15.64

0.95 (6.47%)

15:40
11/20/17
11/20
15:40
11/20/17
15:40
Options
Valeant calls active as shares see relative strength »

Valeant calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jun

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, GIS

General Mills

$54.23

0.51 (0.95%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Periodicals
General Mills, not Nestle, should buy Hain Celestial, Cramer says »

Following a Bloomberg…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

GIS

General Mills

$54.23

0.51 (0.95%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$156.55

0.9 (0.58%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Options
Intuit options imply 5.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SHPG

Shire

$147.37

2.74 (1.89%)

, RHHBY

Roche

$29.10

0.205 (0.71%)

15:32
11/20/17
11/20
15:32
11/20/17
15:32
Recommendations
Shire, Roche analyst commentary  »

Shire selloff on Roche…

SHPG

Shire

$147.37

2.74 (1.89%)

RHHBY

Roche

$29.10

0.205 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

15:30
11/20/17
11/20
15:30
11/20/17
15:30
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Technical Analysis
Technical View: Time Warner drops on pending antitrust briefing »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.74

0.23 (0.67%)

, TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Periodicals
DOJ antitrust announcement concerns AT&T, Time Warner, NBC reports »

Bloomberg also reported…

T

AT&T

$34.74

0.23 (0.67%)

TWX

Time Warner

$87.93

-0.79 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

15:27
11/20/17
11/20
15:27
11/20/17
15:27
Recommendations
Marvell, Cavium, Broadcom analyst commentary  »

Marvell price target…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.